Clinical trial
SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or…
NCT00076349 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00076349 |
|---|---|
| Title | SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) |
| Official title | A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Combination With Rituximab in Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | bendamustine and rituximab |
| Enrollment | 66 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Mar 1, 2008 |
| First posted | Jan 22, 2004 |
| Last update posted | May 9, 2014 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: